Ausio Pharmaceuticals LLC
This article was originally published in Start Up
Ever since the disturbing news broke about the health risks of HRT, drug and vitamin manufacturers have been angling to develop their own products as alternatives. Ausio Pharmaceuticals' candidate is S-equol, a synthetic form of a metabolite found in soy beans that is produced when an isoflavone known as daidzein is broken down by a certain kind of bacteria. Individuals who possess the bacteria and who frequently consume soy products have been shown to have a lower incidence of cardiovascular diseases, menopausal symptoms and certain cancers. Ausio is betting that S-equol can be developed as a pharmaceutical product capable of passing muster with the FDA and other regulatory agencies.
You may also be interested in...
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Advancing the Technological Frontier in AAA Repair," features profiles of Altura Medical, Aptus Endosystems, Endoluminal Sciences and SOVAmed. Plus these Start-Ups Across Health Care: ACT Biotech, Ausio Pharmaceuticals, CureFAKtor Pharmaceuticals, Harbor MedTech and Insituvue.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.